PR Newswire

Implant Sciences Announced as Bronze Sponsor and Exhibitor for AVSEC World 2015 in Dublin, Ireland

Monday, Oct 26, 2015

WILMINGTON, Mass., Oct. 26, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it will exhibit at the 24th AVSEC World conference from October 26-28, 2015 in Dublin, Ireland. Implant Sciences will have its QS-B220 Desktop Explosives and Drugs Trace Detector available for demonstrations in booth 23 and is a bronze sponsor for the event.

The AVSEC World Conference is an annual event organized by ACI, in partnership with ICAO and IATA. AVSEC World 2015, through interactive workshops, panels and expert presentations and with more than 600 delegates, representing the entire industry of security representatives, seeks to facilitate the exchange of ideas and operational experiences, the learning of practical new skills, and putting together the framework to create the future of aviation security.

"Implant Sciences' QS-B220 was truly a disruptive technology in the trace detection industry. With our next-generation non-rad design and patented inCal™ automatic internal calibration, we set out to bring new functionality and advancements to users in an industry which had not seen significant innovation in approximately 20 years," stated Dr. Bill McGann, Implant Sciences' CEO. "We continue to innovate, pioneering the first-of-its-kind networking solution for our ETDs. We look to conferences such as AVSEC World to talk to customers and check the pulse of the industry so we can continue to develop cutting-edge solutions to meet customers' requirements."

"Implant Sciences prides itself on its responsiveness to customer needs. Our approach is to develop products that will solve customer pain points and give them the functionality to make their jobs easier while providing them with the highest level of security possible," added Dr. Darryl Jones, Implant Sciences' Executive Vice President. "We are able to solicit a lot of this valuable Voice of the Customer (VOC) feedback at shows such as AVSEC World. We look forward to our attendance at events such as this and to working with our European partners as they expand the use of ETD to meet the EU aviation requirements."

"We are excited about showcasing Implant Sciences' QS-B220 at AVSEC this year," stated Bob Liscouski, President of Implant Sciences.  "Fiscal year 2015 represented a very good year for us based on our sales to ECAC countries. Sales for our first quarter ended September 30 are strong and on track with our earnings call last month and we believe that we are poised for a successful fiscal 2016."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation

Company Contact:

Robert Liscouski

978-752-1700 x 116  

To view the original version on PR Newswire, visit:

SOURCE Implant Sciences Corporation

OTHER PR Newswire